Ключевые слова
Как цитировать
Аннотация
Осимертиниб — препарат выбора первой линии терапии больных немелкоклеточным раком легкого (НМРЛ) с активирующими мутациями в гене рецептора эпидермального фактора роста (epidermal growth factor receptor — EGFR) и стандарт второй линии для пациентов с мутацией резистентности Т790М после прогрессирования на ингибиторах тирозинкиназ (ИТК) EGFR первого и второго поколений. Осимертиниб обеспечивает высокую эффективность и длительный контроль за болезнью. Однако и к этому препарату неизбежно развивается резистентность. Знание механизмов резистентности поможет определить дальнейшую тактику лечения больных.
Библиографические ссылки
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892-911.
Graham RP, Treece AL, Lindeman NI, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med. 2018;142(2):163-167. https://doi.org/10.5858/arpa.2016-0579-CP.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. https://doi.org/10.1056/NEJMoa0810699.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46. https://doi.org/10.1016/S1470-2045(11)70393-X.
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-34. https://doi.org/10.1200/JCO.2012.44.2806.
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. https://doi.org/10.1126/scitranslmed.3002003.
Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629-640. https://doi.org/10.1056/NEJMoa1612674.
Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536-1544. https://doi.org/10.1016/j.annonc.2020.08.2100.
Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-61. https://doi.org/10.1158/2159-8290.CD-14-0337.
Ahn MJ, Tsai CM, Shepherd FA, et al. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019;125(6):892-901. https://doi.org/10.1002/cncr.31891.
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in UntreatedEGFR-Mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113-25. https://doi.org/10.1056/nejmoa1713137.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50. https://doi.org/10.1056/NEJMoa1913662.
Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130-5140. https://doi.org/10.1158/1078-0432.CCR-16-0399.
Papadimitrakopoulou VA, Wu YL, Han JY, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29:viii741. https://doi.org/10.1093/annonc/mdy424.064.
Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:viii740. https://doi.org/10.1093/annonc/mdy424.063
Le X, Puri S, Negrao MV, et al. Landscape of EGFR-Dependent and -Independent resistance mechanisms to Osimertinib and continuation therapy beyond progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018;24(24):6195-203. https://doi.org/10.1158/1078-0432.ccr-18-1542.
Schoenfeld AJ, Yu HA. The evolving landscape of resistance to Osimertinib. J Thorac Oncol. 2020;15(1):18-21. https://doi.org/10.1016/j.jtho.2019.11.005.
Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725-737. https://doi.org/10.1038/s41416-019-0573-8.
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-92. https://doi.org/10.1056/NEJMoa044238.
Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to Osimertinib. JAMA Oncol. 2018;4(11):1527-1534. https://doi.org/10.1001/jamaoncol.2018.2969.
Lin CC, Shih JY, Yu CJ, et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018;6(2):107-116. https://doi.org/10.1016/S2213-2600(17)30480-0.
DE Carlo E, Schiappacassi M, Pelizzari G, et al. Acquired EGFR C797G mutation detected by liquid biopsy as resistance mechanism after treatment with Osimertinib: A Case Report. In Vivo. 2021;35(5):2941-2945. https://doi.org/10.21873/invivo.12586.
Dong RF, Zhu ML, Liu MM, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res. 2021;167:105583. https://doi.org/10.1016/j.phrs.2021.105583.
Duggirala KB, Lee Y, Lee K. Chronicles of EGFR tyrosine kinase inhibitors: Targeting EGFR C797S containing triple mutations. Biomol Ther (Seoul). 2022;30(1):19-27. https://doi.org/10.4062/biomolther.2021.047.
Schalm SS, Dineen T, Lim SM, et al. 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Ann Oncol. 2020;31:S839. https://doi.org/10.1016/j.annonc.2020.08.1610.
To C, Jang J, Chen T, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 2019;9(7):926-943. https://doi.org/10.1158/2159-8290.CD-18-0903.
Wang S, Song Y, Liu D. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017;385:51-54. https://doi.org/10.1016/j.canlet.2016.11.008.
Maity S, Pai KSR, Nayak Y. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. Pharmacol Rep. 2020;72(4):799-813. https://doi.org/10.1007/s43440-020-00131-0.
Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017;8:14768. https://doi.org/10.1038/ncomms14768.
Wang Y, Yang N, Zhang Y, et al. Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy. J Thorac Oncol. 2020;15(8):1369-1375. https://doi.org/10.1016/j.jtho.2020.04.014.
Haura EB, Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15_suppl):9009-9009. https://doi.org/10.1200/jco.2019.37.15_suppl.9009.
Zhang Y, He B, Zhou D, et al. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. Onco Targets Ther. 2018;12:51-56. https://doi.org/10.2147/OTT.S188612.
Fassunke J, Müller F, Keul M, et al. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun. 2018;9(1):4655. https://doi.org/10.1038/s41467-018-07078-0.
Martinez-Marti A, Felip E, Matito J, et al. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017;28(10):2451-2457. https://doi.org/10.1093/annonc/mdx396.
Deng L, Kiedrowski LA, Ravera E, et al. Response to dual Crizotinib and Osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition. J Thorac Oncol. 2018;13(9):e169-e172. https://doi.org/10.1016/j.jtho.2018.04.007.
Zhu VW, Schrock AB, Ali SM, et al. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification. Lung Cancer (Auckl). 2019;10:21-26. https://doi.org/10.2147/LCTT.S190403.
Giroux-Leprieur E, Dumenil C, Chinet T. Combination of Crizotinib and Osimertinib or Erlotinib might overcome MET-mediated resistance to EGFR tyrosine kinase inhibitor in EGFR-mutated adenocarcinoma. J Thorac Oncol. 2018;13(11):e232-e234. https://doi.org/10.1016/j.jtho.2018.07.012.
Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373-386. https://doi.org/10.1016/S1470-2045(19)30785-5.
Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36(31):3101-3109. https://doi.org/10.1200/JCO.2018.77.7326.
Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8(11):1132-1143. https://doi.org/10.1016/S2213-2600(20)30154-5.
Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol. 2021;39(15_suppl):9006-9006. https://doi.org/10.1200/jco.2021.39.15_suppl.9006
Shu CA, Goto K, Ohe Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. J Clin Oncol. 2022;40(16_suppl):9006-9006. https://doi.org/10.1200/jco.2022.40.16_suppl.9006
Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib study of Telisotuzumab Vedotin in combination with Erlotinib in patients with c-Met protein–expressing non–small-cell lung cancer. J Clin Oncol. 2023;41(5):1105-15. https://doi.org/10.1200/jco.22.00739
Minari R, Bordi P, La Monica S, et al. Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line Osimertinib treatment in a patient with EGFR-mutated NSCLC. J Thorac Oncol. 2018;13(6):e89-e91. https://doi.org/10.1016/j.jtho.2018.03.013.
Ho CC, Liao WY, Lin CA, et al. Acquired BRAF V600E mutation as resistant mechanism after treatment with Osimertinib. J Thorac Oncol. 2017;12(3):567-572. https://doi.org/10.1016/j.jtho.2016.11.2231.
Xie Z, Gu Y, Xie X, et al. Lung adenocarcinoma harboring concomitant EGFR mutations and BRAF V600E responds to a combination of Osimertinib and Vemurafenib to overcome Osimertinib resistance. Clin Lung Cancer. 2021;22(3):e390-e394. https://doi.org/10.1016/j.cllc.2020.06.008.
Eberlein CA, Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75(12):2489-500. https://doi.org/10.1158/0008-5472.CAN-14-3167.
Grazini U, O'Neill DJ, Martin M, et al. PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACRю Cancer Res. 2022;82(12_Suppl):Abstract nr 5353.
Eng J, Woo KM, Sima CS, et al. Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas. J Thorac Oncol. 2015;10(12):1713-9. https://doi.org/10.1097/JTO.0000000000000671.
Rotow J, Patel JD, Hanley MP, et al. Osimertinib and Selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers. J Thorac Oncol. 2021;16:230. https://doi.org/10.1158/1078-0432.ccr-22-2189.
Freydman J, Henshaw L, Patel JV, et al. Combination EGFR and RET inhibition in acquired resistance to Osimertinib in EGFR-mutant NSCLC. Ann Pharmacother. 2022;56(4):503-504. https://doi.org/10.1177/10600280211036909.
Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to Osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8(12):1529-1539. https://doi.org/10.1158/2159-8290.CD-18-1022.
Zeng L, Yang N, Zhang Y. GOPC-ROS1 rearrangement as an acquired resistance mechanism to Osimertinib and responding to Crizotinib combined treatments in lung adenocarcinoma. J Thorac Oncol. 2018;13(7):e114-e116. https://doi.org/10.1016/j.jtho.2018.02.005.
Offin M, Somwar R, Rekhtman N, et al. Acquired ALK and RET gene fusions as mechanisms of resistance to Osimertinib in EGFR-mutant lung cancers. JCO Precis Oncol. 2018;2:PO.18.00126. https://doi.org/10.1200/PO.18.00126.
Qin Q, Li X, Liang X, et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020;11(9):2389-2397. https://doi.org/10.1111/1759-7714.13521.
La Monica S, Fumarola C, Cretella D, et al. Efficacy of the CDK4/6 dual inhibitor Abemaciclib in EGFR-mutated NSCLC cell lines with different resistance mechanisms to Osimertinib. Cancers (Basel). 2020;13(1):6. https://doi.org/10.3390/cancers13010006.
Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37(4):278–85. https://doi.org/10.1200/JCO.18.01585.
Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 Alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784-1793. https://doi.org/10.1016/j.jtho.2019.06.002.
Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line Osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26(11):2654-2663. https://doi.org/10.1158/1078-0432.CCR-19-3563.
Hakozaki T, Kitazono M, Takamori M, et al. Combined small and squamous transformation in EGFR-mutated lung adenocarcinoma. Intern Med. 2020;59(10):1291-4. https://doi.org/10.2169/internalmedicine.3542-19.
Roca E, Gurizzan C, Amoroso V, et al. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treat Rev. 2017;59:117-122. https://doi.org/10.1016/j.ctrv.2017.07.007.
Oizumi S, Sugawara S, Minato K, et al. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open. 2018;3(2):e000313. https://doi.org/10.1136/esmoopen-2017-000313.
Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115-23. https://doi.org/10.1200/jco.19.01488
Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021;6(5):100271. https://doi.org/10.1016/j.esmoop.2021.100271.
Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(11):2544-55. https://doi.org/10.1200/JCO.2005.02.477.
Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15(10):3484-94. https://doi.org/10.1158/1078-0432.CCR-08-2904.
Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-1669. https://doi.org/10.1016/S1470-2045(19)30634-5.
Maemondo M, Fukuhara T, Saito H, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. J Clin Oncol. 2020;38(15_suppl):9506-9506. https://doi.org/10.1200/jco.2020.38.15_suppl.9506
Akamatsu H, Toi Y, Hayashi H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan Oncology Group 8715L phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):386-394. https://doi.org/10.1001/jamaoncol.2020.6758.
Wang J, Garcia Campelo R, Girard N, et al. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure. Ann Oncol. 2022;33:S1597. https://doi.org/10.1016/j.annonc.2022.10.500.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2023